KR950702564A - 비스-스타우로스포린 및 케이-252에이(K-25a)유도체(BIS-STAUROSPORINE AND K-252a DERIVATIVES) - Google Patents

비스-스타우로스포린 및 케이-252에이(K-25a)유도체(BIS-STAUROSPORINE AND K-252a DERIVATIVES)

Info

Publication number: KR950702564A
Authority: KR; South Korea
Prior art keywords: derivatives; bis; staurosporin; staurosporine; disease
Prior art date: 1992-07-24

Application number

KR1019950700251A

Other languages

English (en)

Other versions

KR100276008B1 (ko

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-07-24

Filing date

1995-01-23

Publication date

1995-07-29

1993-07-26 Application filed filed Critical

1995-07-29 Publication of KR950702564A publication Critical patent/KR950702564A/ko

2000-12-15 Application granted granted Critical

2000-12-15 Publication of KR100276008B1 publication Critical patent/KR100276008B1/ko

2013-07-26 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Psychology (AREA)
Virology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
AIDS & HIV (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

KR1019950700251A 1992-07-24 1993-07-26 비스-스타우로스포린 및 케이-252에이 유도체 Expired - Lifetime KR100276008B1 (ko)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US92010292A	1992-07-24	1992-07-24
US07/920102		1992-07-24
PCT/US1993/006974 WO1994002488A1 (en)	1992-07-24	1993-07-26	BIS-STAUROSPORINE AND K-252a DERIVATIVES

Publications (2)

Publication Number	Publication Date
KR950702564A true KR950702564A (ko)	1995-07-29
KR100276008B1 KR100276008B1 (ko)	2000-12-15

Family

ID=25443161

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1019950700251A Expired - Lifetime KR100276008B1 (ko)	1992-07-24	1993-07-26	비스-스타우로스포린 및 케이-252에이 유도체

Country Status (18)

Country	Link
US (1)	US5461146A (ko)
EP (4)	EP1002534B1 (ko)
JP (3)	JP3762427B2 (ko)
KR (1)	KR100276008B1 (ko)
AT (3)	ATE152111T1 (ko)
AU (1)	AU675236B2 (ko)
BR (1)	BR9306789A (ko)
CA (1)	CA2140924A1 (ko)
DE (3)	DE69333874T2 (ko)
DK (3)	DK0768312T3 (ko)
ES (3)	ES2101331T3 (ko)
GR (2)	GR3023817T3 (ko)
HK (1)	HK1028206A1 (ko)
HU (5)	HU0301601D0 (ko)
NO (2)	NO305481B1 (ko)
NZ (2)	NZ286198A (ko)
PT (1)	PT768312E (ko)
WO (1)	WO1994002488A1 (ko)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5621101A (en) *	1992-07-24	1997-04-15	Cephalon, Inc.	Protein kinase inhibitors for treatment of neurological disorders
US5756494A (en) *	1992-07-24	1998-05-26	Cephalon, Inc.	Protein kinase inhibitors for treatment of neurological disorders
DE4243321A1 (de) *	1992-12-21	1994-06-23	Goedecke Ag	Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
KR100201343B1 (ko) *	1993-05-28	1999-06-15	바바라 에스 쉴버그	인돌로카르바졸 유도체들의 전립선의 병적상태치료에의 용도
US5468872A (en) *	1993-09-16	1995-11-21	Cephalon, Inc.	K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5541347A (en) *	1993-12-07	1996-07-30	Eli Lilly And Company	Synthesis of bisindolylmaleimides
US5843935A (en) *	1993-12-07	1998-12-01	Eli Lilly And Company	Protein kinase C inhibitors
US5624949A (en) *	1993-12-07	1997-04-29	Eli Lilly And Company	Protein kinase C inhibitors
HUT69164A (en) *	1993-12-07	1995-08-28	Lilly Co Eli	Improved process for producing bis-indolyl-maleimide derivatives
ES2162843T3 (es) *	1993-12-07	2002-01-16	Lilly Co Eli	Inhibidores de la proteina quinasa c.
US5723456A (en) *	1993-12-07	1998-03-03	Eli Lilly & Company	Therapeutic treatment for cardiovascular diseases
DK0817627T3 (da) *	1993-12-23	2005-06-06	Lilly Co Eli	Inhibitorer af proteinkinase C
AU1911095A (en) *	1994-02-18	1995-09-04	Cephalon, Inc.	Aqueous indolocarbazole solutions
KR100464907B1 (ko) *	1994-10-26	2005-07-04	세파론, 인코포레이티드	신경계질환치료용단백질키나아제억제제
US5650407A (en) *	1995-04-05	1997-07-22	Cephalon, Inc.	Selected soluble esters of hydroxyl-containing indolocarbazoles
US5686444A (en) *	1995-04-05	1997-11-11	Cephalon, Inc.	Selected soluble esters of hydroxyl-containing indolocarbazoles
US5808060A (en) *	1995-12-11	1998-09-15	Cephalon, Inc.	Fused isoindolones
US6232299B1 (en)	1996-05-01	2001-05-15	Eli Lilly And Company	Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
EP1019043A4 (en) *	1996-05-07	2003-07-30	Univ Pennsylvania	INHIBITORS OF GLYCOGEN SYNTHESIS KINASE 3 AND METHOD FOR THEIR IDENTIFICATION AND USE
UA67725C2 (en)	1996-06-03	2004-07-15	Cephalon Inc	K-252a derivatives and a method for improvement of functioning and cell survival enhancement
US6875865B1 (en) *	1996-06-03	2005-04-05	Cephalon, Inc.	Selected derivatives of K-252a
PT912184E (pt)	1996-06-25	2002-12-31	Cephalon Inc	Utilizacao de um derivado de k-252a para o tratamento de doencas do sietma nervoso central ou periferico e sobre-producao de citoquina
US7144997B2 (en)	1997-07-24	2006-12-05	Curis, Inc.	Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
AU737092B2 (en) *	1997-08-15	2001-08-09	Cephalon, Inc.	Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
WO1999033836A1 (en) *	1997-12-31	1999-07-08	Cephalon, Inc.	3'-epimeric k-252a derivatives
US6811992B1 (en) *	1998-05-14	2004-11-02	Ya Fang Liu	Method for identifying MLK inhibitors for the treatment of neurological conditions
US6127401A (en) *	1998-06-05	2000-10-03	Cephalon, Inc.	Bridged indenopyrrolocarbazoles
US6013646A (en) *	1998-07-02	2000-01-11	Bayer Corporation	Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6200968B1 (en)	1998-08-06	2001-03-13	Cephalon, Inc.	Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) *	1998-08-06	2010-09-14	Cephalon, Inc.	Particle-forming compositions containing fused pyrrolocarbazoles
NZ511024A (en)	1998-09-25	2003-10-31	Cephalon Inc	Methods for preventing/treating damage to sensory hair cells, loss of hearing and cochlear neurons using fused pyrrolocarbazoles
CA2347519A1 (en)	1998-10-13	2000-04-20	Kyowa Hakko Kogyo Co., Ltd.	An agent for treating ophthalmopathy
US6242473B1 (en) *	1999-01-08	2001-06-05	Maxim Pharmaceuticals, Inc.	Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
US6841567B1 (en)	1999-02-12	2005-01-11	Cephalon, Inc.	Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6323215B1 (en)	1999-07-09	2001-11-27	Ortho-Mcneil Pharmaceutical, Inc.	Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods
CA2379149A1 (en)	1999-07-09	2001-01-18	Ortho-Mcneil Pharmaceutical, Inc.	Neurotrophic pyrrolidines and piperidines, and related compositions and methods
WO2001042243A2 (en) *	1999-12-08	2001-06-14	Advanced Medicine, Inc.	Protein kinase inhibitors
US20020002169A1 (en) *	1999-12-08	2002-01-03	Griffin John H.	Protein kinase inhibitors
US7129250B2 (en)	2000-05-19	2006-10-31	Aegera Therapeutics Inc.	Neuroprotective and anti-proliferative compounds
CA2417744A1 (en) *	2000-07-31	2002-02-07	The Regents Of The University Of California	Model for alzheimer's disease and other neurodegenerative diseases
DE10113513A1 (de) *	2001-03-20	2002-10-02	Medinnova Ges Med Innovationen	Kombinationspräparat zur Prophylaxe und/oder Therapie von Nervenzell- und/oder Gliazellschäden durch ein neues Behandlungsverfahren
GB0117645D0 (en) *	2001-07-19	2001-09-12	Isis Innovation	Therapeutic stratergies for prevention and treatment of alzheimers disease
IL161156A0 (en)	2001-10-30	2004-08-31	Novartis Ag	Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
US20050130877A1 (en) *	2003-03-14	2005-06-16	Children's Medical Center Corporation	Axon regeneration with PKC inhibitors
US6664266B2 (en) *	2002-03-14	2003-12-16	Children's Medical Center Corporation	Axon regeneration with PKC inhibitiors
CA2393720C (en)	2002-07-12	2010-09-14	Eli Lilly And Company	Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
DE10255343B4 (de) *	2002-11-27	2006-09-07	Nad Ag	N,N-Verbrückte, Stickstoff-Substituierte Carbacyclische Indolocarbazole als Proteinkinase-Inhibitoren
US20040175384A1 (en) *	2003-12-12	2004-09-09	Mohapatra Shyam S.	Protein kinase C as a target for the treatment of respiratory syncytial virus
CA2533861A1 (en)	2003-08-08	2005-02-17	Novartis Ag	Combinations comprising staurosporines
US8592368B2 (en)	2003-12-19	2013-11-26	University Of South Florida	JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
US8076320B2 (en)	2004-02-27	2011-12-13	Cephalon, Inc.	Crystalline forms of a pharmaceutical compound
JP5704785B2 (ja) *	2004-07-19	2015-04-22	ザ・ジョンズ・ホプキンス・ユニバーシティ	免疫抑制のためのｆｌｔ３阻害剤
CN100513850C (zh) *	2005-08-23	2009-07-15	浙江华夏阀门有限公司	三角截面密封套
WO2007022999A1 (en) *	2005-08-25	2007-03-01	Creabilis Therapeutics S.P.A.	Polymer conjugates of k-252a and derivatives thereof
CA2622867A1 (en)	2005-09-16	2007-03-22	Schering Corporation	Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
EA014433B1 (ru)	2005-10-11	2010-12-30	Мерк Патент Гмбх	Egfr-зависимая модуляция экспрессии хемокинов, влияние на терапию и диагностику опухолей и её побочные эффекты
US20100150944A1 (en) *	2007-04-16	2010-06-17	Modgene, Llc	Methods and compositions for diagnosis and treatment of depression and anxiety
WO2009067221A2 (en) *	2007-11-20	2009-05-28	Cephalon, Inc.	Microemulsion containing indolocarbazole compound and dosage forms containing the same
KR102228358B1 (ko)	2012-12-21	2021-03-16	쉬케후세트 솔란데트 에이치에프	신경 장애 및 통증의 ｅｇｆｒ 표적 치료
WO2019090205A1 (en) *	2017-11-06	2019-05-09	Snap Bio, Inc.	Pim kinase inhibitor compositions, methods, and uses thereof
WO2024018245A1 (en)	2022-07-22	2024-01-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of calpain inhibitors for the treatment of the diabetic kidney disease
WO2024153744A1 (en)	2023-01-20	2024-07-25	Institut National de la Santé et de la Recherche Médicale	Autophagy activators for the treatment of rhabdomyolysis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4554402A (en) *	1983-12-23	1985-11-19	Aluminum Company Of America	Vibration damper for overhead conductor
JPS62102388A (ja) *	1985-10-29	1987-05-12	Toppan Printing Co Ltd	Ｉｃカ−ド
JPS62155285A (ja) *	1985-12-27	1987-07-10	Kyowa Hakko Kogyo Co Ltd	生理活性物質ｋ−２５２の誘導体
JPS62155284A (ja) *	1985-12-27	1987-07-10	Kyowa Hakko Kogyo Co Ltd	生理活性物質ｋ−２５２の誘導体
JPS62220196A (ja) *	1986-03-20	1987-09-28	Kyowa Hakko Kogyo Co Ltd	新規物質ｕｃｎ―０１
US4816450A (en) *	1986-09-15	1989-03-28	Duke University	Inhibition of protein kinase C by long-chain bases
JPH0826036B2 (ja) *	1987-01-22	1996-03-13	協和醗酵工業株式会社	生理活性物質ｋ−２５２の誘導体
JPH0826037B2 (ja) *	1987-01-22	1996-03-13	協和醗酵工業株式会社	生理活性物質ｋ−２５２の誘導体
US4735939A (en) *	1987-02-27	1988-04-05	The Dow Chemical Company	Insecticidal activity of staurosporine
EP0303697B1 (en) *	1987-03-09	1997-10-01	Kyowa Hakko Kogyo Co., Ltd.	Derivatives of physiologically active substance k-252
IL86632A0 (en) *	1987-06-15	1988-11-30	Ciba Geigy Ag	Derivatives substituted at methyl-amino nitrogen
US5093330A (en) *	1987-06-15	1992-03-03	Ciba-Geigy Corporation	Staurosporine derivatives substituted at methylamino nitrogen
JPH07113027B2 (ja) *	1987-12-24	1995-12-06	協和醗酵工業株式会社	Ｋ−２５２誘導体
JPH0725786A (ja) *	1990-05-16	1995-01-27	Univ Rockefeller	アルツハイマー病を伴うアミロイドーシスの治療
AU2322392A (en) *	1991-07-03	1993-02-11	Regeneron Pharmaceuticals, Inc.	Method and assay system for neurotrophin activity
DE4133605C2 (de) *	1991-10-10	1994-05-11	Siemens Ag	Flexibler Roboterarm
AU3064992A (en) *	1991-11-08	1993-06-07	University Of Southern California	Compositions containing k-252 compounds for potentiation of neurotrophin activity
DE4217964A1 (de) *	1992-05-30	1993-12-02	Goedecke Ag	Indolocarbazol-Imide und deren Verwendung

1993
- 1993-07-22 US US08/096,561 patent/US5461146A/en not_active Expired - Lifetime
- 1993-07-26 HU HU0301601A patent/HU0301601D0/hu unknown
- 1993-07-26 AT AT93917337T patent/ATE152111T1/de not_active IP Right Cessation
- 1993-07-26 WO PCT/US1993/006974 patent/WO1994002488A1/en active IP Right Grant
- 1993-07-26 DK DK96116661T patent/DK0768312T3/da active
- 1993-07-26 DE DE69333874T patent/DE69333874T2/de not_active Expired - Lifetime
- 1993-07-26 AT AT96116661T patent/ATE196142T1/de not_active IP Right Cessation
- 1993-07-26 DK DK99120008T patent/DK1002534T3/da active
- 1993-07-26 BR BR9306789A patent/BR9306789A/pt not_active Application Discontinuation
- 1993-07-26 CA CA002140924A patent/CA2140924A1/en not_active Abandoned
- 1993-07-26 EP EP99120008A patent/EP1002534B1/en not_active Expired - Lifetime
- 1993-07-26 ES ES93917337T patent/ES2101331T3/es not_active Expired - Lifetime
- 1993-07-26 DE DE69310178T patent/DE69310178T2/de not_active Expired - Lifetime
- 1993-07-26 AT AT99120008T patent/ATE304848T1/de not_active IP Right Cessation
- 1993-07-26 DE DE69329397T patent/DE69329397T2/de not_active Expired - Lifetime
- 1993-07-26 EP EP96116661A patent/EP0768312B1/en not_active Expired - Lifetime
- 1993-07-26 ES ES96116661T patent/ES2151629T3/es not_active Expired - Lifetime
- 1993-07-26 AU AU46881/93A patent/AU675236B2/en not_active Expired
- 1993-07-26 JP JP50473194A patent/JP3762427B2/ja not_active Expired - Lifetime
- 1993-07-26 HU HU0301601A patent/HU225341B1/hu unknown
- 1993-07-26 HU HU0301425A patent/HU225342B1/hu unknown
- 1993-07-26 DK DK93917337.3T patent/DK0651754T3/da active
- 1993-07-26 ES ES99120008T patent/ES2248950T3/es not_active Expired - Lifetime
- 1993-07-26 HU HU0301425A patent/HU0301425D0/hu unknown
- 1993-07-26 EP EP04025114A patent/EP1512688A1/en not_active Withdrawn
- 1993-07-26 HU HU9500192A patent/HU225297B1/hu unknown
- 1993-07-26 EP EP93917337A patent/EP0651754B1/en not_active Expired - Lifetime
- 1993-07-26 PT PT96116661T patent/PT768312E/pt unknown
- 1993-07-26 NZ NZ286198A patent/NZ286198A/en not_active IP Right Cessation
- 1993-07-26 NZ NZ254662A patent/NZ254662A/en not_active IP Right Cessation
- 1993-07-26 KR KR1019950700251A patent/KR100276008B1/ko not_active Expired - Lifetime
1995
- 1995-01-23 NO NO950242A patent/NO305481B1/no not_active IP Right Cessation
1997
- 1997-06-19 GR GR970401455T patent/GR3023817T3/el unknown
1999
- 1999-02-05 NO NO990542A patent/NO307446B1/no not_active IP Right Cessation
2000
- 2000-11-21 HK HK00107421A patent/HK1028206A1/xx not_active IP Right Cessation
- 2000-11-28 GR GR20000402623T patent/GR3034917T3/el not_active IP Right Cessation
2002
- 2002-08-23 JP JP2002244111A patent/JP3723533B2/ja not_active Expired - Fee Related
2005
- 2005-01-27 JP JP2005019891A patent/JP2005170955A/ja active Pending

Also Published As

Publication number	Publication date
EP0768312B1 (en)	2000-09-06
HU0301601D0 (en)	2003-08-28
ES2248950T3 (es)	2006-03-16
DE69333874T2 (de)	2006-05-04
HK1028206A1 (en)	2001-02-09
HU9500192D0 (en)	1995-03-28
WO1994002488A1 (en)	1994-02-03
HU225297B1 (en)	2006-09-28
DK1002534T3 (da)	2006-01-23
GR3023817T3 (en)	1997-09-30
ATE196142T1 (de)	2000-09-15
EP0768312A2 (en)	1997-04-16
HU225342B1 (en)	2006-10-28
ATE304848T1 (de)	2005-10-15
HUT71239A (en)	1995-11-28
DE69329397D1 (de)	2000-10-12
EP1002534B1 (en)	2005-09-21
ES2151629T3 (es)	2001-01-01
JP3762427B2 (ja)	2006-04-05
AU4688193A (en)	1994-02-14
DE69333874D1 (de)	2006-02-02
DK0768312T3 (da)	2000-12-11
NO305481B1 (no)	1999-06-07
NZ286198A (en)	2001-06-29
EP1512688A1 (en)	2005-03-09
NO307446B1 (no)	2000-04-10
PT768312E (pt)	2001-03-30
JP2005170955A (ja)	2005-06-30
EP0768312A3 (en)	1997-06-04
NZ254662A (en)	1996-11-26
EP0651754A1 (en)	1995-05-10
AU675236B2 (en)	1997-01-30
DE69310178T2 (de)	1997-09-25
ES2101331T3 (es)	1997-07-01
BR9306789A (pt)	1998-12-08
DE69310178D1 (de)	1997-05-28
CA2140924A1 (en)	1994-01-25
NO950242L (no)	1995-03-07
JP2003113184A (ja)	2003-04-18
HU0301425D0 (en)	2003-07-28
US5461146A (en)	1995-10-24
HU225341B1 (en)	2006-10-28
NO990542D0 (no)	1999-02-05
EP1002534A1 (en)	2000-05-24
NO990542L (no)	1999-02-05
JPH08501080A (ja)	1996-02-06
GR3034917T3 (en)	2001-02-28
KR100276008B1 (ko)	2000-12-15
DK0651754T3 (da)	1997-10-27
EP0651754A4 (en)	1995-08-09
DE69329397T2 (de)	2001-03-15
NO950242D0 (no)	1995-01-23
EP0651754B1 (en)	1997-04-23
ATE152111T1 (de)	1997-05-15
JP3723533B2 (ja)	2005-12-07

Publication	Publication Date	Title
KR950702564A (ko)	1995-07-29	비스-스타우로스포린 및 케이-252에이(K-25a)유도체(BIS-STAUROSPORINE AND K-252a DERIVATIVES)
EP0363415A4 (en)	1993-03-17	Compounds for the treatment of alzheimer's disease
ES2177665T3 (es)	2002-12-16	Inhibidores de proteina quinasa para el tratamiento de trastornos neurologicos.
NO944075D0 (no)	1994-10-26	Fremgangsmåte for fremstilling av (S)-3-amino-1-substituert pyrrolidiner
NO944339D0 (no)	1994-11-14	Melatoninderivater for anvendelse ved behandling av sövnforstyrrelser
FI881413A0 (fi)	1988-03-24	Foerfarande foer framstaellning av 3'-azido-3'-deoxitymidin.
IT1271567B (it)	1997-05-30	Procedimento per l'ulteriore trattamento di salcicce
FI883759A (fi)	1989-02-15	C.12-modifierade etromycin a-derivat.
NO903338L (no)	1991-01-29	Fremgangsmaate for mikrobiologisk fremstilling av l-carnitin.
GR3034688T3 (en)	2001-01-31	Use of 6,7-substituted-2-aminotetralines for preparing pharmaceutical compositions useful for the treatment of septic shock, and antipyretic and antiinflammatory pharmaceutical compositions
AU7078691A (en)	1991-08-21	Use of urapidile and derivatives for treating arteriosclerotic diseases
AU7715291A (en)	1991-11-21	Treatment of horses using ethylestrenol
NO171565C (no)	1993-03-31	Fremgangsmaate for behandling av manganslam

Legal Events

Date	Code	Title	Description
1995-01-23	PA0105	International application	Patent event date: 19950123 Patent event code: PA01051R01D Comment text: International Patent Application
1995-07-29	PG1501	Laying open of application
1997-08-30	A201	Request for examination
1997-08-30	PA0201	Request for examination	Patent event code: PA02012R01D Patent event date: 19970830 Comment text: Request for Examination of Application
1999-05-21	E902	Notification of reason for refusal
1999-05-21	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 19990521 Patent event code: PE09021S01D
2000-07-27	E701	Decision to grant or registration of patent right
2000-07-27	PE0701	Decision of registration	Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20000727
2000-09-26	GRNT	Written decision to grant
2000-09-26	PR0701	Registration of establishment	Comment text: Registration of Establishment Patent event date: 20000926 Patent event code: PR07011E01D
2000-09-26	PR1002	Payment of registration fee	Payment date: 20000927 End annual number: 3 Start annual number: 1
2000-12-15	PG1601	Publication of registration
2001-04-02	G170	Re-publication after modification of scope of protection [patent]
2003-09-16	PR1001	Payment of annual fee	Payment date: 20030917 Start annual number: 4 End annual number: 4
2004-09-21	PR1001	Payment of annual fee	Payment date: 20040922 Start annual number: 5 End annual number: 5
2005-09-22	PR1001	Payment of annual fee	Payment date: 20050923 Start annual number: 6 End annual number: 6
2006-09-20	PR1001	Payment of annual fee	Payment date: 20060921 Start annual number: 7 End annual number: 7
2007-09-20	PR1001	Payment of annual fee	Payment date: 20070921 Start annual number: 8 End annual number: 8
2008-09-23	PR1001	Payment of annual fee	Payment date: 20080924 Start annual number: 9 End annual number: 9
2009-09-18	PR1001	Payment of annual fee	Payment date: 20090921 Start annual number: 10 End annual number: 10
2010-09-07	PR1001	Payment of annual fee	Payment date: 20100908 Start annual number: 11 End annual number: 11
2011-09-06	PR1001	Payment of annual fee	Payment date: 20110907 Start annual number: 12 End annual number: 12
2012-09-14	FPAY	Annual fee payment	Payment date: 20120917 Year of fee payment: 13
2012-09-14	PR1001	Payment of annual fee	Payment date: 20120917 Start annual number: 13 End annual number: 13
2013-07-27	EXPY	Expiration of term
2013-07-27	PC1801	Expiration of term	Termination date: 20140126 Termination category: Expiration of duration